Đăng xuất
Local Infection: Infections of the nasal airways should be appropriately treated but do not constitute a specific contraindication to treatment with Flixonase.
The full benefit of Flixonase may not be achieved until treatment has been administered for several days.
Care must be taken while transferring patients from systemic steroid treatment to Flixonase, if there is any reason to suppose that their adrenal function is impaired.
Although Flixonase will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may, in certain instances, necessitate appropriate additional therapy, particularly to control eye symptoms.
Use in pregnancy: There is inadequate evidence of safety in human pregnancy. In animal reproduction studies, adverse effects typical of potent corticosteroids are only seen at high systemic exposure levels; direct intranasal application ensures systemic exposure. However, as with other drugs, the use of Flixonase during human pregnancy requires that the benefits be weighed against the possible risk associated with Flixonase or with any alternative therapy.
Use in lactation: It is not known whether fluticasone propionate is excreted in human breast milk, nor are there any data available from animal studies. However, following intranasal administration to primates, no drug was detected in the plasma, and it is therefore unlikely that the drug would be detectable in milk.
